Since cancer cells of epithelial origin can express IL-1R2 [43, 44], it is possible that in our case cetuximab/EGFR inhibition may be inducing the release of IL-1β as well as IL-1α but we are unable to detect IL-1β due to rapid binding by sIL-1R2. The gene discussed is IL1A; the disease is cancer.